argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of g…
| Periodo | 2026-10 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $7.32 | $5.52 | $8.02 |
| Estimado | $-27.83 | $6.19 | $4.92 | $6.11 |
| Sorpresa | — | +18.3% | +12.2% | +31.3% |
| Métrica | ARGX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 89.1% | 57.4% | +31.8% |
| Operating Margin | 25.4% | -34.4% | +59.8% |
| Net Margin | 31.1% | -32.5% | +63.6% |
| FCF Margin | 16.4% | -12.6% | +28.9% |
| ROE | 17.6% | -39.2% | +56.8% |
| ROA | 14.9% | -30.9% | +45.8% |
| Current Ratio | 5.23 | 2.73 | +2.50 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 14.9% | — |
| ✓Flujo de caja operativo positivo | $685M | −$83M |
| ✓Rentabilidad sobre activos al alza | 14.9% | 13.4% |
| ✗Caja operativa/activos supera al ROA | 7.9% | ROA 14.9% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 5.23 | 7.29 |
| ✗Sin aumentar el nº de acciones | 66M | 65M |
| ✗Margen bruto al alza | 89.1% | 89.6% |
| ✓Rotación de activos al alza | 0.48 | 0.35 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 16.4% |
| ✓ROCE > 10 % | 14.3% |
| ✓Ventas > 5 %/año (3 años) | 645.3% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 33.0% |
Riesgo de quiebra (Altman Z 24.3): zona segura
ARGENX SE cotiza a 819.14 USD y tiene una capitalización bursátil de $51.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud